A large phase III trial conducted at 74 hospitals across the United Kingdom assessed the efficacy of 2 drugs, carboplatin and docetaxel, in treating patients with advanced triple-negative breast cancers (TNBCs). The study took place from 2008-2014, involving 376 patients who were equally allocated to receive either carboplatin or docetaxel, to determine the drug's objective response rate (ORR). Results concluded that "in patients with germline-mutated BRCA 1/2 breast cancer, carboplatin had double the ORR of docetaxel, 68% vs. 33%."
To read more about this study, click here
Study mentioned: Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine; Published online 30 April 2018. doi:10.1038/s41591-018-0009-7.
No comments:
Post a Comment